Asymmetric STN DBS for FOG in Parkinson's disease: A pilot trial.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
06 2019
Historique:
received: 20 10 2018
revised: 20 02 2019
accepted: 20 02 2019
pubmed: 4 3 2019
medline: 10 5 2020
entrez: 4 3 2019
Statut: ppublish

Résumé

In Parkinson's disease (PD), freezing of gait (FOG) is a highly disabling gait disorder. Though deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an efficient treatment for advanced PD, the management of STN DBS refractory FOG remains challenging. To evaluate the long-term impact on FOG of unilateral stimulation reduction in PD treated with bilateral STN DBS. Patients with bilateral STN DBS for at least one year and refractory FOG were included in a randomized, double blind, cross-over clinical trial. They were randomized to chronic (CHR) vs. experimental (EXP) stimulation (30% amplitude reduction contralateral to the least affected body side), each condition for 4 weeks. Gait and FOG were assessed both in the OFF and ON medication conditions. Primary outcome was the difference in the FOG percentage during gait assessment and in a composite gait score in CHR vs. EXP stimulation. The study was stopped early for futility. Of the 12 patients included, eight dropped out because of re-emerging of PD symptoms. In the four patients who sustained the experimental condition, the FOG percentage did not improve, whether in the OFF (CHR: 13.4% vs. EXP: 16.8%) or in the ON (CHR: 19.5% vs. EXP: 19.8%) medication condition. There was no change in the composite gait score (CHR: 5.5 ± 1.3 vs. EXP: 6.3 ± 3.3). Most patients did not tolerate the unilateral amplitude reduction of STN DBS in the long-term. Moreover, this strategy failed to improve FOG in patients who could sustain the procedure. CLINICALTRIAL. NCT02704195.

Sections du résumé

BACKGROUND
In Parkinson's disease (PD), freezing of gait (FOG) is a highly disabling gait disorder. Though deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an efficient treatment for advanced PD, the management of STN DBS refractory FOG remains challenging.
OBJECTIVE
To evaluate the long-term impact on FOG of unilateral stimulation reduction in PD treated with bilateral STN DBS.
METHODS
Patients with bilateral STN DBS for at least one year and refractory FOG were included in a randomized, double blind, cross-over clinical trial. They were randomized to chronic (CHR) vs. experimental (EXP) stimulation (30% amplitude reduction contralateral to the least affected body side), each condition for 4 weeks. Gait and FOG were assessed both in the OFF and ON medication conditions. Primary outcome was the difference in the FOG percentage during gait assessment and in a composite gait score in CHR vs. EXP stimulation.
RESULTS
The study was stopped early for futility. Of the 12 patients included, eight dropped out because of re-emerging of PD symptoms. In the four patients who sustained the experimental condition, the FOG percentage did not improve, whether in the OFF (CHR: 13.4% vs. EXP: 16.8%) or in the ON (CHR: 19.5% vs. EXP: 19.8%) medication condition. There was no change in the composite gait score (CHR: 5.5 ± 1.3 vs. EXP: 6.3 ± 3.3).
CONCLUSIONS
Most patients did not tolerate the unilateral amplitude reduction of STN DBS in the long-term. Moreover, this strategy failed to improve FOG in patients who could sustain the procedure. CLINICALTRIAL.
GOV IDENTIFIER
NCT02704195.

Identifiants

pubmed: 30826266
pii: S1353-8020(19)30078-1
doi: 10.1016/j.parkreldis.2019.02.032
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02704195']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-99

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Sara Meoni (S)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France; Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France.

Bettina Debȗ (B)

Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France.

Pierre Pelissier (P)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France.

Emma Scelzo (E)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France.

Anna Castrioto (A)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France; Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France.

Eric Seigneuret (E)

Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France; Department of Neurosurgery, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France.

Stephan Chabardes (S)

Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France; Department of Neurosurgery, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France.

Valerie Fraix (V)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France; Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France.

Elena Moro (E)

Division of Neurology, Movement Disorders Unit, CHU of Grenoble, Grenoble Alpes University, Avenue Maquis du Grésivaudan, 38700, Grenoble, France; Grenoble Alpes University, INSERM U1216, Grenoble Institut Neuroscience, 38000, Grenoble, France. Electronic address: elenamfmoro@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH